Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FX-322 for acquired sensorineural hearing loss
NCT05086276Phase 2Completed
- Sponsor
- Frequency Therapeutics
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FX-322 in sensorineural hearing loss (SNHL), sponsored by Frequency Therapeutics. Started Oct 2021; status: completed.
02
Drugs
FX-322
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT05086276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086276.